Electronic Cigarettes as a Harm Reduction Strategy Among People With Opioid Use Disorder on Buprenorphine
NCT ID: NCT07202039
Last Updated: 2025-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
90 participants
INTERVENTIONAL
2026-01-05
2030-02-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluating the Pharmacokinetics and Patient Outcomes of Buprenorphine Microdosing
NCT05307458
Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper
NCT02737826
Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers
NCT02250664
Effects of Buprenorphine/Naloxone Administered in Different Ways For Treating Opioid Dependence
NCT00134914
Low-dose Buprenorphine Initiation for Opioid Use Disorder
NCT05450718
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sweet-Cooling EC + Counseling
Those randomized to the intervention group will be provided a free 12-week supply of sweet-cooling electronic cigarette (EC) liquid and five brief, individual counseling sessions, and asked to try to switch completely to EC.
Brief individual counseling sessions
Five brief, individual counseling sessions will provide education, behavioral support, and motivational strategies to facilitate switching from combustible cigarette use to EC
Sweet non-cooling EC + Counseling
Those randomized to the intervention group will be provided a free 12-week supply of sweet non-cooling electronic cigarette (EC) liquid and five brief, individual counseling sessions, and asked to try to switch completely to EC.
Brief individual counseling sessions
Five brief, individual counseling sessions will provide education, behavioral support, and motivational strategies to facilitate switching from combustible cigarette use to EC
Tobacco-flavored EC + Counseling
Those randomized to the intervention group will be provided a free 12-week supply of tobacco-flavored electronic cigarette (EC) liquid and five brief, individual counseling sessions, and asked to try to switch completely to EC.
Brief individual counseling sessions
Five brief, individual counseling sessions will provide education, behavioral support, and motivational strategies to facilitate switching from combustible cigarette use to EC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Brief individual counseling sessions
Five brief, individual counseling sessions will provide education, behavioral support, and motivational strategies to facilitate switching from combustible cigarette use to EC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Smoke ≥5 CPD for ≥1 year
* Daily CC smoker
* Willing to switch to EC
* Exhaled CO ≥6 ppm
* Diagnosed with OUD
* Stable on bupropion treatment
* In good physical and mental health
* Able to use a smartphone
* Willing to participate in all study components
Exclusion Criteria
* Use of EC on ≥4 of the past 30 days
* Use of other tobacco products (e.g., cigars, smokeless tobacco) on ≥9 days of the past 30 days
* Use of nicotine replacement therapy, smoking cessation medication, or a cessation attempt in the past 30 days
* Hypertension
* Medical condition that would contraindicate participation
* Meet DSM-V criteria for major depressive episode, psychotic episode, or manic episode
* Current suicidal ideation or suicide attempt in the past year
* Psychiatric hospitalization in the past year
* Contemplating pregnancy, currently pregnant, or breastfeeding
* Unable to speak and/or read English
21 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Prisma Health-Upstate
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Irene Pericot-Valverde
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Addiction Medicine Center
Greenville, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2328661-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.